Long-term Impact in Intensive Care Survivors of Coronavirus Disease (COVID-19)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-29

Study Completion Date

2023-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Investigator seeks to evaluate the long term neurological and pulmonary sequelae of COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-ICU Follow-up Study in Covid-19 Patients

NCT05299346

COVID-19 Pandemic Intensive Care Unit Syndrome Delirium

COMPLETED

Recovery of Patients From COVID-19 After Critical Illness

NCT04401254

COVID-19 Critical Illness

COMPLETED

Long Term Outcome in ICU Treated COVID-19: New Chronic Diseases

NCT05075096

Covid19

COMPLETED

ICU Recovery in Australian Patients

NCT02225938

Intensive Care Unit Syndrome

COMPLETED

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

NCT03738774

Post Intensive Care Syndrome

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent data suggests that survivors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or (COVID-19) report adverse health status, including neurological and cognitive deficits and impaired pulmonary function, even months after discharge. Adult COVID-19 survivors after ICU stay, who are noted to have increased mortality and organ failure, are at higher risk of long-term disabilities and impaired quality of life. This study is one branch of a multi-site study coordinated by Gilead Sciences, in which participants who were critically ill with COVID-19 will be followed at three and nine months after discharge to test pulmonary function, cognitive function, and quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically suspected or laboratory confirmed COVID-19 infection by real-time PCR
* Admission to an intensive care unit for COVID-19 and discharge

Exclusion Criteria

* Pregnancy
* Participants unable to complete long-term follow-up due to logistical problems
* Participant paralyzed before being admitted to hospital for COVID-19
* History of pulmonary resection
* Previous pulmonary transplant
* Documented advanced neurologic order for which the patient is unable to carry out 6 minute walk test
* Documented psychiatric disease for which the patient is unable to carry out interview

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No